Business
Exicure, Inc. Reports Full Year 2024 Financial Results
CHICAGO, March 18, 2025--Exicure, Inc. Reports Full Year 2024 Financial Results
About this update from Exicure, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2431,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/e2635272423b969819a062b60db18fed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EmtNMMPG_xy9LteKlHZ.pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e2635272423b969819a062b60db18fed","width":960,"height":237},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9C1719OcfwZ2_zjvgzmSZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e2635272423b969819a062b60db18fed","width":1200,"height":296}},"lazy":false},{"type":"text","content":"CHICAGO, March 18, 2025--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.","length":706,"tagName":"p"},{"type":"text","content":"2024 Financial Results","length":22,"tagName":"p"},{"type":"text","content":"Cash Position: Cash and cash equivalents were $12.5 million as of December 31, 2024, as compared to $0.8 million as of December 31, 2023. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify.","length":379,"tagName":"p"},{"type":"text","content":"Research and Development (R&D) Expense: Research and development expenses were $0 for the year ended December 31, 2024, as compared to $1.4 million for the year ended December 31, 2023. The decrease in R&D expense for the year ended December 31, 2024 of $1.4 million reflects the stoppage of clinical, preclinical, and discovery program activit...